The agreement provides comprehensive licensing rights and patent protection relating to Canopus’s Phase II oncology drug candidate, CB1400. Canopus BioPharma expects to develop CB1400 as a method for preventing and reducing mucositis.
Canopus BioPharma’s CB1400, a former anti-schistosomal drug, is currently in Phase II clinical development by Canopus as an anti-mucositis preventative agent in patients receiving radio or chemotherapy treatment.
Patrick Prendergast, chairman and CEO of Canopus, said: “Securing the rights to the Wisconsin Alumni Research Foundation (WARF) patents strengthens Canopus BioPharma’s intellectual property position for future licensing opportunities of CB1400, one of our most exciting products.”